If you build industrial and manufacturing facilities for a living, you have probably watched the pharmaceutical construction wave from the outside. The projects are large, the timelines are compressed, and you know your teams could execute the work. Yet the same handful of firms keep winning, and by the time an RFP reaches you the shortlist already feels set. The reason is simpler and harder than most contractors expect: on a major pharmaceutical facility program, the field of contractors allowed to compete is largely decided twelve to eighteen months before the RFP is written, and capability is almost never what decides it. What decides it is whether the people who shape these projects already know who you are.
That is an uncomfortable thing to hear if you have spent years building a strong firm. It is also the most useful thing to understand before you spend another quarter chasing solicitations you were never positioned to win.
Why pharmaceutical construction turned into a requirement, not a trend
The current buildout is not another ordinary cycle of demand. In April 2026 the federal government placed a 100 percent tariff on many imported patented pharmaceuticals and their active ingredients, and gave manufacturers a limited set of ways out. Building in the United States became the way to protect a product's economics, not simply a way to add capacity.
The mechanism matters, because it sets the clock every buyer is now working against. Proclamation 11020, issued under Section 232 and signed on April 2, 2026, created the tariff and two doors out of it. A manufacturer can file an onshoring plan approved by the Department of Commerce, which brings a reduced rate through April 2030, or reach a pricing agreement with Health and Human Services, which drops the tariff through January 2029. The phase-in ran on two dates: July 31, 2026 for seventeen named large manufacturers, and September 29, 2026 for all other importers. Generics, biosimilars, orphan drugs, product already made in the United States, and certain specialty categories were exempted. An earlier version of the tariff announced for October 1, 2025 was postponed and never took effect. Markets grow on their own; what changed here is the floor underneath this one, a policy clock that turns domestic capacity into a condition of selling the product, with April 2030 as the horizon nearly every capital plan is now measured against.
Layered onto reshoring that was already underway and the demand surge behind GLP-1 therapies, that clock turned a building trend into a building requirement. The pledged numbers are real: fourteen manufacturers, among them AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and Eli Lilly, have committed roughly $480 billion in United States investment. One caution worth keeping in front of you: the construction-addressable share of that figure is large, but it is not $480 billion, and no contractor should size a market-entry decision off the headline. Lilly opened the wave in late February 2025 with a $27 billion program across four United States sites for active ingredients and sterile injectables, one of them a $5.3 billion facility in Lebanon, Indiana. Roughly seventy-eight percent of the registered active-ingredient facilities that supply the United States still sit offshore, which is the imbalance the whole policy is built to correct.
Who decides which contractors are allowed to compete
The pharmaceutical company issues the RFP, but it rarely sets the field alone. By the time a solicitation goes out, the roster of contractors treated as credible has usually been shaped over the previous twelve to eighteen months by three groups: the life sciences architecture and engineering (A/E) firms, the commissioning, qualification, and validation (CQV) partners, and the owner's representatives who advise on delivery. These are the people a manufacturer trusts to tell them which builders can be relied on inside a regulated environment. The RFP then validates a direction that has already been set rather than opening a new one.
For a contractor, that changes where the real competition happens. There are three doors into the consideration set, and all three are relationships rather than bids: the life sciences A/E firms, the CQV partners, and the owner's reps. A contractor unknown to those firms was never in the pursuit to begin with, which is why so many capable builders experience the loss as a surprise. They were not outbid. They were absent from a decision that happened a year before they saw the paperwork.
What the buyer is really afraid of
The person who owns the contractor decision, usually a VP of facilities engineering, a director of capital projects, or a head of global manufacturing engineering, is not weighing you mainly on price. They are weighing the risk you represent to a regulated environment and to their own name inside it.
The motivations will look familiar to any contractor: speed to market, cost, compliance, capacity; the fear underneath them is what sets pharmaceutical work apart. In most construction, a contractor failure is a schedule problem or a budget problem. In pharmaceutical work it can become a regulatory event, a cGMP deviation, a commissioning delay, or an inspection finding, and a problem of that kind follows a facilities leader through the rest of their career in a market small enough that people remember. That buyer also does not sit alone. Operations, real estate, research and development, procurement, legal, environmental health and safety, and quality all have a seat, and any one of them can stop a selection. You are not selling to a single decision-maker. You are arming one person to defend a choice to everyone else at the table.
That is the line I come back to with contractors entering this market. Nobody at that table is worried about your bid. They are worried about standing in front of an inspector explaining a decision they made about you.
In our work at illi, we map technical buyers to a small set of archetypes, and this one is a Regulatory Protector: the buyer whose first instinct about any decision is whether it will hold up under inspection. What that person carries is both organizational and personal, and the two are easy to conflate and costly to confuse. The organizational fear is a compliance failure that delays a product launch or draws a finding on an audit. The personal fear is being the name attached to that failure, on a project everyone in the industry can name, in a career where that story travels. A contractor who speaks only to cost and schedule is answering a question this buyer is not actually asking.
How other contractors broke in
The contractors who entered this market recently did not win their way in on a single landmark project. They built a position first, usually through one of three moves, and the work followed.
ARCO National took the adjacency route. In 2024 it stood up a dedicated practice, ARCO Life Science and Advanced Manufacturing, built out from advanced-manufacturing capability it already had, and its early client roster came to include Johnson & Johnson, GSK, Bayer, Watson-Marlow, and MilliporeSigma. Skyline Construction, which is one hundred percent employee-owned, took the opposite route of depth over breadth: its credibility was carried by a single practice leader credited with more than sixty lab build-outs and over three million square feet across thirty years. The market trusted a person before it trusted a portfolio. Evans General Contractors chose proximity, opening a Raleigh office to sit inside the Research Triangle where the work is concentrated rather than trying to reach it from a distance.
The clearest signal came from STO Building Group, which hired Jennie Taveras as its Life Sciences Sector Leader in November 2024. Taveras is a chemical engineer with a bachelor's and master's from NYU, and she came from Bristol Myers Squibb and Sanofi Pasteur. One credible hire of that kind changes the story a firm can tell overnight, because it gives the market a name it already trusts. Under all three moves sits the same pattern: an entry point where existing capability translates directly, ecosystem relationships built before any pharmaceutical portfolio exists, and at least one credible person the market can point to.
Why capability is not the variable
Most contractors who want this work already have the capability to do it. That is exactly why capability does not decide who wins. When every serious bidder can build the facility, the decision moves to who the buyer and their advisors already trust, and that trust is built in the roughly two years before a first project ever appears on a bid list.
Four things move a contractor from capable to considered, and none of them is capability. The first is treating the credibility timeline as the go-to-market it is, which means the eighteen to twenty-four months before a first project is real business development, not dead time. The second is ecosystem positioning, being known to the A/E firms, CQV partners, and owner's reps who set the field. The third is visibility in buyer research, showing up as a credible builder when a facilities leader or someone on their team looks you up, in the places they look. The fourth is the right entry point, the tenant improvements, lab renovations, non-cGMP scopes, and speculative developer projects that build a verifiable record before anyone expects a pharmaceutical portfolio.
How that plays out depends on the buyer. Big pharma runs preferred-vendor lists and formal prequalification, with pursuits that can stretch across long cycles. Mid-size manufacturers and contract development and manufacturing organizations keep shorter lists and move more on relationships. Emerging biotech tends to source contractors through its investor and advisor network rather than any list at all. One honest caveat: the specific cycle lengths we use internally, on the order of twelve to thirty-six months for big pharma and six to twenty-four for mid-size and CDMO work, are our own read from the market rather than published figures, and you should treat them as directional.
Where the work begins
The contractors who break into pharmaceutical construction are not the most capable ones. They are the ones who became known and trusted before the market started looking, and they did the unglamorous positioning work in the window when it did not yet look like winning work. That is the part most firms skip, because chasing a live RFP feels productive and building credibility for a project that does not exist yet does not.
illi is a B2B strategy and story agency for technical companies, based in Chicago. We work with industrial and manufacturing contractors on strategy, story, and market presence, the positioning that gets a capable builder into the right rooms before the RFP is written. If you are watching the pharmaceutical buildout and know your firm belongs in it, the most useful conversation right now is about the eighteen months in front of your next bid, not the bid itself. You can reach me at nicole@illi-agency.com.
Common questions
When is the contractor field for a pharmaceutical project decided?
Usually twelve to eighteen months before the RFP is issued. By then the life sciences A/E firms, the CQV partners, and the owner's representatives advising the project have already shaped which contractors are treated as credible. The RFP tends to confirm that direction rather than open a new one, which is why contractors unknown to those advisors rarely make the shortlist.
Do you need a cGMP portfolio to enter pharmaceutical construction?
No. Most contractors enter through adjacent work: tenant improvements, lab renovations, non-cGMP scopes, and speculative developer projects. That work builds a verifiable record and the relationships that matter before a buyer expects a pharmaceutical-specific portfolio. A single credible hire or practice leader often carries more weight with buyers than a long project list.
Why do the same firms keep winning pharmaceutical construction work?
Because the decision rewards trust over capability. When every serious bidder can build the facility, the buyer and their advisors default to firms they already know and can defend to an inspector. Being known to the project's advisors, the A/E firms, CQV partners, and owner's reps, in the year before the RFP is what separates the firms that win from the equally capable firms that never appear.
What is driving the current wave of United States pharmaceutical construction?
An April 2026 federal proclamation placed a 100 percent tariff on many imported patented drugs and their key ingredients, with relief tied to building domestic capacity through 2029 and 2030. Layered onto reshoring that was already underway and demand for GLP-1 therapies, that turned domestic manufacturing construction into a compliance-driven requirement rather than an optional expansion.
.webp)
